LDL-C Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day to10 mg/Day in Chinese ACS(Acute Coronary Syndrome) Patients

NCT02077257 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

1060

Enrollment

OTHER

Sponsor class

Conditions

Acute Coronary Syndrome

Interventions

DRUG: Rosuvastatin

Sponsor

Committee of Cardio-Cerebral-Vascular Diseases of GSC

Collaborators

[object Object]